Original paper

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

Blood21.00
Volume: 134, Issue: 9, Pages: 761 - 764
Published: Jul 12, 2019
Abstract
Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or incidence of histological transformation. We performed a retrospective analysis of a population-based cohort of 296 patients with advanced-stage FL treated with frontline BR and maintenance rituximab. As previously demonstrated, outcomes with this regimen are excellent,...
Paper Details
Title
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma
Published Date
Jul 12, 2019
Journal
Volume
134
Issue
9
Pages
761 - 764
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.